Griseofulvin

CLINICAL USE

Antifungal agent:Dermatophyte infections of the skin, scalp, hair and nails

DOSE IN NORMAL RENAL FUNCTION

500 mg daily, in divided doses or as a single dose, in severe infection dose may be doubled

PHARMACOKINETICS

  • Molecular weight                           :352.8
  • %Protein binding                           :84
  • %Excreted unchanged in urine     : <1
  • Volume of distribution (L/kg)       :1.2–1.41
  • half-life – normal/ESRD (hrs)      :9–24/20

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

  • 20 to 50     : Dose as in normal renal function
  • 10 to 20     : Dose as in normal renal function
  • <10           : Dose as in normal renal function

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD                :Not dialysed. Dose as in normal renal function
  • HD                     :Not dialysed. Dose as in normal renal function
  • HDF/high flux   :Not dialysed. Dose as in normal renal function
  • CAV/VVHD      :Not dialysed. Dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugs

  • Anticoagulants: metabolism of coumarins accelerated (reduced anticoagulant effect)
  • Ciclosporin: griseofulvin possibly reduces ciclosporin concentration (two reports of such an interaction in literature)Oestrogens and progestogens: metabolism of oral contraceptives accelerated (reduced contraceptive effect)

    ADMINISTRATION

    Reconstition

    Route

    Oral

    Rate of Administration

    Comments

    OTHER INFORMATION

    Use with extreme caution in patients with SLE.

  • Related News